Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-6 in pediatric atopic dermatitis
NCT02031445Phase 2Terminated
- Sponsor
- Celsus Therapeutics PLC
- Start
- Aug 2014
- Primary completion
- Mar 2015
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MRX-6 Arm with Placebo Arm (2 arms). Primary endpoint: Investigator's Global Assessment at 4 weeks. Started Aug 2014; status: terminated.
02
Drugs
EB02
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02031445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02031445.